Contrast Enhanced Mammography Market Size, Share, Growth Analysis, By Applications(Screening and Diagnosis), By End User(Hospital, Diagnostic Centres, Specialty Clinics, Others), By Region - Industry Forecast 2025-2032

Contrast Enhanced Mammography Market size was valued at USD 1.94 Billion in 2023 and is poised to grow from USD 2.04 Billion in 2024 to USD 3.07 Billion by 2032, growing at a CAGR of 5.28% during the forecast period (2025-2032).

Some of the major players engaged in the market are Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Medical Systems, Planmed Oy. Other players include, Metaltronica, Carestream Health, and General Medical Merate. The market is also experiencing the entry of new players, which is expected to intensify competition in the coming years. 'Hologic Inc.', 'GE Healthcare', 'Siemens Healthineers AG', 'Koninklijke Philips N.V.', 'Fujifilm Holdings Corporation', 'Dilon Technologies Inc.', 'Planmed Oy', 'Metaltronica S.p.A.', 'CMR Naviscan Corporation', 'General Medical Merate S.p.A.', 'Delphinus Medical Technologies Inc.', 'Micrima Limited', 'KUB Technologies Inc.', 'Aurora Imaging Technology Inc.', 'Carestream Health Inc.', 'Planmed Oy', 'Zebra Medical Vision Ltd.', 'Volpara Health Technologies Ltd.', 'iCAD Inc.', 'Agfa-Gevaert NV', 'In October 2023, Hologic and Bayer announced a collaborative effort to advance contrast-enhanced mammography (CEM) adoption across Asia Pacific, Canada, and Europe. This pioneering technique involves administering iodinated contrast intravenously and utilizing both low-energy and high-energy X-rays, akin to digital mammography. The iodine selectively absorbs high-energy X-rays, potentially improving cancer detection accuracy. ', 'In October 2023, Syracuse became the hub for cutting-edge breast cancer imaging technology with the installation of two 3-D mammography units at Crouse Hospital. This state-of-the-art technology aims to detect cancerous tumors at earlier stages and enhance cancer detection in denser breast tissue. ', 'In June 2023, Bayer announced that its iodine-based contrast agent, Ultravist (iopromide)-300, -370, received approval from the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography (CEM). This approval makes Ultravist the only contrast agent authorized for this specific indication. The product is intended for visualizing known or suspected breast lesions in adults, serving as an adjunct to mammography and/or ultrasound. CEM is an emerging imaging modality that combines digital mammography with the administration of a contrast agent like Ultravist to aid in the identification of breast lesions. '

The major factor driving the market growth is rising incidence of breast cancer. Breast cancer is the most common cancer among women worldwide. It is possible to treat breast cancer extremely effectively, especially if the disease is diagnosed early. A breast cancer patient is generally treated with surgery, radiation therapy, and medications (hormone therapy, chemotherapy, and/or targeted biological therapy) to treat the microscopic cancer that has spread from the breast tumor. Treatments such as these can prevent cancer growth and spread, thereby saving lives.

Every year, the incidence of breast cancer in women rises, along with the market expansion and the number of treatments available. Enhanced techniques for breast cancer diagnostics using advanced technologies. More sophisticated technologies for the early detection of breast cancer have improved performance in terms of efficiency, accuracy, efficacy, dependability, and speed of results.

The North America region is anticipated to dominate the global contrast enhanced mammography market. The presence of large players, established diagnostic and screening infrastructure, technological breakthroughs, high patient awareness, and reimbursement regulations are the main drivers of this region's dominance.